About us

Captor Therapeutics is a biotech company focused on the development of degraders of difficult-to-drug molecular targets. A combined experience of the Captor's team will allow for the identification of first-in-class drug candidates in the treatment of oncology and chronic inflammation. 

Backed by over 20 mln EUR from NCBR and private investors, we initiated three R&D projects aiming at advancing a protein degradation platform. We collaborate closely with renowned biology and chemistry experts from top American and European academic institutions.

We are operating in the Wrocław Technological Park in state-of-the-art laboratories in Poland.






Our main goal is silencing of disfunctional proteins on the post-translational level. To this end we are using a broad spectrum of chemical biology methods. Currently, we are developing first-in-class molecules to treat various pathological conditions, e.g. cancer and autoimmune diseases.

Today, biologics (antibodies or their fragments) represent the main therapeutic modality for the treatment of many of the  autoimmune and inflammatory conditions. Many of these biologics control the pathogenic process by interjecting with either surface receptor proteins or their extracellular ligands. The main disadvantage of this approach is that pathogenic proteins often play roles in more than one downstream signaling processes. Inhibition of these receptors by antibodies dysregulates pathogenic but also beneficial molecular pathways, which ultimately leads to severe side effects of targeted therapies. In Captor Therapeutics, through our proprietary protein degradation platform, we selectively target only downstream pathogenic signaling activated by the aforementioned receptors, while preserving the beneficial pathways. This approach is used to intervene in autoimmune, inflammatory and neurodegenerative diseases.

Spontaneous mutations often abrogate interactions between E3 ubiquitin ligases and their partner proteins. This may result in accumulation of the latter, leading to dysregulation of molecular signalling and ultimately to tumorigenesis. Captor Therapeutics has developed a molecular repair platform that is capable of reconstituting interactions between ubiquitin ligases and their molecular partners, which restores cellular homeostasis and prevents cancer progression.


Currenty we are working on four co-funded grant projects:


Development of the platform for the identification of a first-in-class allosteric modulators (POIR.04.01.02-00-0147/16)
The aim of the project is the development of a high-content, high-throughput and sensitive assay that reports on small molecule degraders. The lack of such technology pose the bottleneck in rapid design of small molecules degraders. Captor Therapeutics assay is robust, versatile and scalable.
This is a project with a 1 mln EUR budget run in collaboration with Institute of Immunology and Experimental Therapy, Polish Academy of Sciences.​ The National Centre of Research and Development supports the project through 0.8 mln EUR grant-aid. 

Development and implementation of an innovative platform for the identification drug-like compounds (POIR.04.01.04-00-0116/16)
The aim of the project is the development of DegScreen technology - a two-step, efficient, high-throughput assay for identification of active compounds with therapeutic potential. 
DegScreen is a project with a 1.1 mln EUR budget, run in collaboration with EIT+ Wroclaw Research Center. The National Centre of Research and Development supports the project through 0.9 mln EUR grant-aid. 

Development of first-in-class anti-inflammatory drugs specifically degrading cell surface receptors (POIR.01.01.01-00-0747/16)
The aim of the project is the development of small molecules interfering with the pathological signalling in chronic inflammation, e.g. psoriasis or psoriatic arthritis.
Using the in-house-developed technology, we will identify small molecular weight compounds, which will be tested in animals after fulfilling efficacy and ADMET parameters criteria. 
Project has a 8.2 mln EUR budget for years 2017-2022. The National Centre of Research and Development supports the project through 6.2 mln EUR grant-aid. 

Inducing apoptosis with small molecules as therapeutic intervention in multiple severe malignancies (POIR.01.01.01-00-0956/17)

The aim of the project is to develop small molecule compounds that will constitute a paradigm shift in the treatment of multiple severe malignancies.

Project has a 8.5 mln EUR budget for years 2018-2023. The National Centre of Research and Development supports the project through 6.4 mln EUR grant-aid. 


Degradation of proteins is a relatively new approach in drug development. We are developing low molecular weight compounds capable of inducing degradation of targeted proteins in vivo. These compounds can be further developed into new therapeutics with limited side effects and convenient routes of administration. One of the most substantial features of our drug candidates is the fact that their efficiency is not dependent on the enzymatic or binding function of the protein of interest, therefore we are also able to target the so-called “undruggable” proteome.

Captor Therapeutics' drug discovery platform is based on an array of chemical biology tools that hijacks intracellular protein degradation machinery. Our expertise covers also allosteric modulation of proteins (allostery platform), fragment-based drug discovery (FBDD), structure-based drug design (SBDD) and phenotypic screenings.


The company’s mode of action is presented on the scheme – we communicate with doctors and patients to identify areas which suffer from an urging need for novel therapeutics (for example due to substantial side effects of known drugs, their limited effectiveness, or no drugs being available at all). Then, using our proprietary screening platform and a tailored library of chemical structures developed by our chemists and biochemists we identify possible drug candidates towards selected disease-related molecular targets (proteins of interest). After collecting the initial research data and confirming the desired activity of the future drug we move first to pre-clinical, and then to clinical trials. At this point a close partnership between researchers, clinicians and patients is required to gather large amounts of significant and conclusive data which enable us to bring the new therapeutic to the market.

Our Team




Captor Therapeutics is constantly seeking qualified employees. If you feel like embarking upon a rocket science drug discovery venture, you are fed up with academia and eager to solve all sort of problems on the fly, you will enjoy working with us.

We are looking for a biotech all-arounder, who for the last couple of years performed various types of experiments, who knows how to fix technical problems and glitches, and who gladly shares her/his knowledge and experience with younger members of the team.

Do not hesitate to apply. Please use the links provided in each job. Our newest job offers are enlisted below:

Show map